Compare SVRE & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SVRE | DRMA |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8M | 2.1M |
| IPO Year | 2022 | 2021 |
| Metric | SVRE | DRMA |
|---|---|---|
| Price | $0.92 | $2.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 64.9K | 54.5K |
| Earning Date | 12-21-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $580,536.00 | N/A |
| Revenue This Year | $453.30 | N/A |
| Revenue Next Year | $106.57 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.19 | N/A |
| 52 Week Low | $0.77 | $2.34 |
| 52 Week High | $63.60 | $23.70 |
| Indicator | SVRE | DRMA |
|---|---|---|
| Relative Strength Index (RSI) | 38.69 | 33.27 |
| Support Level | $0.86 | $2.92 |
| Resistance Level | $0.98 | $3.16 |
| Average True Range (ATR) | 0.09 | 0.29 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 53.94 | 22.56 |
Saverone 2014 Ltd provides driver protection solutions. The company develops and deploys ADAS technologies for transportation safety and driver assistance. The company's product restricts the driver from surfing, communicating, and receiving alerts while driving. The company has developed a system that provides a solution to the problem of distracted driving caused by cell phone use, which endangers the driver, passengers, other drivers on the road and pedestrians. Geographially, it operates in Israel and Europe, out of which it derives maximum revenue from Israel.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.